Profits will drop as patents expire, and chemical-based therapies are eclipsed by biotech
(Newser) -
Patent protections on some of the pharmaceutical industry's best-selling drugs, like Lipitor, Plavix and Singulair, are due to expire in the next several years, and drug manufacturers have little in the pipeline to replace them. The drug companies will lose billions—as much as half their combined revenue—to generic...
More »
